Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
SOCS7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SOCS3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SOCS4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SOCS5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SDCCAG8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SDCCAG8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SIGIRR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SIGIRR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SMAGP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SMAGP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SOCS1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SOCS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RTN4RL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of RTN4RL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RXFP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of RXFP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SCARA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SCARA5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
247
248
249
250
251
>>
2926
>